# A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

> **NCT05260411** · PHASE3 · COMPLETED · sponsor: **Akeso** · enrollment: 246 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **BIOLOGICAL:** AK102
- **BIOLOGICAL:** AK102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05260411
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-26
- **Primary completion:** 2022-12-19
- **Final completion:** 2022-12-19
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05260411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05260411, "A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05260411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*